Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finance Watch: Alternative Funding Sources Crucial Even Amidst A Biopharma VC Boom

Executive Summary

Private Company Edition: Investments by CIRM, the GHIT fund and the European Investment Bank back early-stage science and treatments for neglected diseases. Also, Versant Ventures raises $700m in two funds. In VC deals, Akero raised $70m, Impel NeuroPharma brought in $67.5m.

Advertisement

Related Content

Why The M&A Boom Many Expected In 2018 Didn’t Happen
US Biopharma IPOs Surge, Data For 2018 So Far
Finance Watch: Not Everyone Can Go Public, But Biopharma IPOs Are Using Multiple Markets
Finance Watch: VC Tally Hits $14.5bn For 2018, Beating 2017 With A Quarter Left To Go
Venture Funding Deals: Atreca Raises $125m To Advance Solid Tumor Candidate
Deal Watch: Takeda Teams With Molecular Templates On Anti-CD38 Approach To Multiple Myeloma
Akero Thinks It Will Produce A Next-Wave Therapy For NASH With Former Amgen Compound
VC Roundup: Flagship’s New Fund Designed To Raise Its Stake In Startups
Aprea Banks $51m Series B To Tackle 'Holy Grail' Of Oncology
CIRM asks patients how to spend last $800m for stem cell therapies

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124355

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel